CCRM

We're pleased to share our 2025 #annualreport: Reimagining The Possible. It was a year defined by resilience, focus & forward momentum. Read about our collab w/ @IonQ_Inc, progress w/ @CCRM_au & Nordic, successes at our #GMP #CDMO & @CATTI_Training & more ccrm.ca/regenerative-m…

Allogeneic cell therapy is often discussed as though it were a single modality moving along a single development path. That framing is increasingly unhelpful. - Arnaud Deladeriere for @OutsourcedPharm outsourcedpharma.com/doc/let-s-stop…

Ready to scale-up your impact on Canadian life sciences? Applications are now open for Cohort IX of the adMare Executive Institute, Canada's premier leadership development program designed specifically for senior executives and emerging C-suite leaders in Canada’s life sciences sector. Participants join a nation-wide community of leaders from across the life sciences ecosystem, building the skills, networks, and peer relationships that help companies grow and careers thrive. Cohort IX runs August 2026 to February 2027. Space is limited, so submit your application early. Apply by July 24, 2026: admarebio.com/en/executive-i… --- Prêt à augmenter votre impact dans les sciences de la vie au Canada? Les candidatures sont maintenant ouvertes pour la cohorte IX de l’Institut pour cadres supérieurs d’adMare, le programme de développement du leadership par excellence au Canada, conçu spécialement pour les cadres supérieurs et les leaders émergents du C-suite dans le secteur canadien des sciences de la vie. Les participants rejoignent une communauté nationale de leaders issus de tout l'écosystème des sciences de la vie, développant les compétences, les réseaux et les relations entre pairs qui aident les entreprises à se développer et les carrières à prospérer. La cohorte IX se déroulera d’août 2026 à février 2027. Le nombre de places est limité ; soumettez donc votre candidature dès que possible. Postulez avant le 24 juillet 2026 : admarebio.com/fr/institut-po…

Despite their innovation & leadership, women-led companies still face barriers when it comes to securing funding & support. The #OBIO Women in Health Initiative Seed Program is breaking barriers for women-led companies with funding up to $10K, coaching & more.

How do we separate fact from fiction in CGTs? To kick off season 5 of #CCRMpodcast, @heysciencesam & Megan Munsie discuss the growing challenge of misinformation, the risks it poses to patients & innovation, & more. Listen where you stream podcasts or at ccrm.ca/podcast.

@AndyDonovan64 Good luck Andy!

After seven and a half incredible years, it's time for me to turn the page. To our members, sponsors, volunteers, Board of Directors, and my colleagues—thank you for your trust, partnership, and friendship. Thank you, LSO. It's been an unforgettable journey.

@RySciComms Sad news. @Signalsblogs just blogged about Sam Neill's cancer situation last week. It's too bad that he didn't have longer cancer-free. signalsblog.ca/right-turn-how…

Everything Sam Neill Shared About His Blood Cancer, From Symptoms to Treatment Updates & CAR T cell therapy today.com/health/celebri…

The 2026 Cells I See #sciart contest is accepting cell images & artwork that capture the beauty of cells seen directly through the microscope or through the interpretive lens of the artist. The Grand Prize winner will receive $750. Learn more at cellsisee.ccrm.ca

What a terrific episode! We know we're biased, but are also confident that you will like it too. Thanks to the hosts, @STEMCELLTech and @ISSCR. cc: @MichaelMay5, @JanetRothberg

$25k. One winner. Endless impact. 👩‍🔬🚀 Know someone that’s shaking up Ontario’s #LifeSciences sector? This is your last week to recognize them! Nominate them for the Baylis Ontario Life Sciences Innovator Award—and help bring their leading-edge work into the spotlight. Deadline: July 20 🔗 oce.formstack.com/forms/2026_bay… @BaylisMedTech

The fifth season of the #CCRMpodcast drops on July 15 🎉 Listen for interviews with CGT experts who share insider insights and info on timely topics. Find and follow “Commercializing Living Therapies with CCRM” to get notified, or listen at ccrm.ca/podcast

2/2 A new peer-reviewed article in Cytotherapy, co-published by ARM and several of our members, highlights the manufacturing models, costs, and opportunities for CAR-T cell therapy. Read it here: isct-cytotherapy.org/article/S1465-…

Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook - @ErinHarris_1 for @_CellandGene cellandgene.com/doc/dr-peter-m…

The world has changed. Engineering has too. PEO is reviewing the Professional Engineers Act and exploring how engineering should be defined, licensed and regulated in the years ahead. Share your feedback through our survey by July 18: ow.ly/gEsV50ZmpcQ

The cell and gene therapy treatment landscape looks very different today than it did in 2018. 📄🧬 Early CGT delivery in the U.S. was almost entirely concentrated in academic centers built around specialized infrastructure and clinical expertise. alliancerm.org/arm-whitepaper… 1/2

Editor @msstaceyerin says celebrities can help advance cell and gene therapies in a variety of ways and points to the @MichaelJFoxOrg as perhaps the best example of celebrity impact, with @EBResearch making significant progress in #EpidermolysisBullosa signalsblog.ca/right-turn-how…

CCRM is pleased to announce a partnership with @STEMCELLTech to expand access to matched GMP & RUO iPSC lines for #celltherapy development. This gives developers a faster, lower-risk path from research to the clinic. ccrm.ca/wp-content/upl…

Gene therapy is changing the way we think about treating disease, shifting the focus from managing symptoms to addressing conditions at their genetic source. It's an exciting area of innovation, and one where Canadian companies are helping move the field forward. As highlighted in this recent article, adMare portfolio company @SpecificBio is among the innovators advancing next-generation gene-editing technologies with the potential to improve patient outcomes. We're proud to support companies developing breakthrough science with the potential to make a real-world impact. Read the full article here: hospitalnews.com/gene-therapy-i… #GeneTherapy #LifeSciences #Innovation

Join us in Kyoto for a landmark celebration of 20 years of iPSC science. The global stem cell community will convene for the iPSC 20th Anniversary Symposium, featuring advances in science, bioengineering, ethics, and policy. Register 👉 bit.ly/49jDNXN

🚨👇Clinical fellows interested in cell and gene therapy applications #celltherapy #genetherapy #immunotherapy #cancer #autoimmune #hemoglobinopathies

3M+ Californians live with knee #osteoarthritis. With $12M from CIRM, @genascence is advancing investigational gene therapy GNSC-001, designed to reduce inflammation, pain, and cartilage damage. Early data are promising; a larger trial is next. Read more: bit.ly/3QA4aCf